-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $46 Price Target

Benzinga·03/26/2025 14:16:36
Listen to the news
Cantor Fitzgerald analyst Ross Osborn reiterates Sanara MedTech (NASDAQ:SMTI) with a Overweight and maintains $46 price target.